These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12644359)

  • 1. Substance P serum levels are increased in major depression: preliminary results.
    Bondy B; Baghai TC; Minov C; Schüle C; Schwarz MJ; Zwanzger P; Rupprecht R; Möller HJ
    Biol Psychiatry; 2003 Mar; 53(6):538-42. PubMed ID: 12644359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment.
    Deuschle M; Sander P; Herpfer I; Fiebich BL; Heuser I; Lieb K
    Psychiatry Res; 2005 Jul; 136(1):1-6. PubMed ID: 16024091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of substance P and response to antidepressant pharmacotherapy.
    Lieb K; Walden J; Grunze H; Fiebich BL; Berger M; Normann C
    Pharmacopsychiatry; 2004 Sep; 37(5):238-9. PubMed ID: 15470802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression.
    Münchau A; Langosch JM; Gerschlager W; Rothwell JC; Orth M; Trimble MR
    J Neurol Neurosurg Psychiatry; 2005 Apr; 76(4):527-33. PubMed ID: 15774440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saliva levels of 3-methoxy-4-hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression.
    Egami M; Imamura Y; Nabeta H; Mizoguchi Y; Yamada S
    Hum Psychopharmacol; 2013 Jan; 28(1):7-14. PubMed ID: 23124792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
    Szegedi A; Müller MJ; Anghelescu I; Klawe C; Kohnen R; Benkert O
    J Clin Psychiatry; 2003 Apr; 64(4):413-20. PubMed ID: 12716243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the clinical efficacy of mirtazapine.
    Benkert O; Muller M; Szegedi A
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S23-6. PubMed ID: 12404666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Care of depressed patients with anxiety symptoms.
    Nutt DJ
    J Clin Psychiatry; 1999; 60 Suppl 17():23-7; discussion 46-8. PubMed ID: 10446738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
    Hong CJ; Hu WH; Chen CC; Hsiao CC; Tsai SJ; Ruwe FJ
    J Clin Psychiatry; 2003 Aug; 64(8):921-6. PubMed ID: 12927007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.
    Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA;
    J Clin Psychiatry; 2008 Sep; 69(9):1404-15. PubMed ID: 19193341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirtazapine compared with paroxetine in major depression.
    Benkert O; Szegedi A; Kohnen R
    J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.
    Schatzberg AF; Kremer C; Rodrigues HE; Murphy GM;
    Am J Geriatr Psychiatry; 2002; 10(5):541-50. PubMed ID: 12213688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder.
    Jung YE; Jun TY; Kim KS; Bahk WM
    Int J Clin Pharmacol Ther; 2011 Jul; 49(7):437-43. PubMed ID: 21726494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A monoamine oxidase B gene variant and short-term antidepressant treatment response.
    Tadić A; Rujescu D; Müller MJ; Kohnen R; Stassen HH; Dahmen N; Szegedi A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1370-7. PubMed ID: 17640790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging.
    Smith DF; Stork BS; Wegener G; Ashkanian M; Jakobsen S; Bender D; Audrain H; Vase KH; Hansen SB; Videbech P; Rosenberg R
    Psychopharmacology (Berl); 2009 Sep; 206(1):133-40. PubMed ID: 19536526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.